Unrelated allogeneic bone marrow-derived mesenchymal stem cells for steroid-refractory acute graft-versus-host disease

A phase I/II study

Kazuo Muroi, Koichi Miyamura, Kazuteru Ohashi, Makoto Murata, Tetsuya Eto, Naoki Kobayashi, Shuichi Taniguchi, Masahiro Imamura, Kiyoshi Ando, Shunichi Kato, Takehiko Mori, Takanori Teshima, Masaki Mori, Keiya Ozawa

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

We conducted a multicenter phase I/II study using mesenchymal stem cells (MSCs) manufactured from the bone marrow of healthy unrelated volunteers to treat steroid-refractory acute graft-versus-host disease (aGVHD). Fourteen patients with hematological malignancies who suffered from grade II (9 patients) or III aGVHD (5) were treated. Affected organs were gut (10 patients), skin (9 patients), and liver (3 patients). Seven patients had two involved organs. The median age was 52. No other second-line agents were given. MSCs were given at a dose of 2 × 106 cells/kg for each infusion twice a week for 4 weeks. If needed, patients were continuously given MSCs weekly for an additional 4 weeks. By week 4, 13 of 14 patients (92.9 %) had responded to MSC therapy with a complete response (CR; n = 8) or partial response (PR; n = 5). At 24 weeks, 11 patients (10 with CR and 1 with PR) were alive. At 96 weeks, 8 patients were alive in CR. A total of 6 patients died, attributable to the following: underlying disease relapse (2 patients), breast cancer relapse (1), veno-occlusive disease (1), ischemic cholangiopathy (1), and pneumonia (1). No clear adverse effects associated with MSC infusion were observed. Third party-derived bone marrow MSCs may be safe and effective for patients with steroid-refractory aGVHD.

Original languageEnglish
Pages (from-to)206-213
Number of pages8
JournalInternational Journal of Hematology
Volume98
Issue number2
DOIs
Publication statusPublished - 2013 Aug

Fingerprint

Graft vs Host Disease
Mesenchymal Stromal Cells
Bone Marrow
Steroids
Recurrence
Hematologic Neoplasms
Cell- and Tissue-Based Therapy
Pneumonia
Healthy Volunteers

Keywords

  • GVHD
  • Mesenchymal stem cells
  • Steroid

ASJC Scopus subject areas

  • Hematology

Cite this

Unrelated allogeneic bone marrow-derived mesenchymal stem cells for steroid-refractory acute graft-versus-host disease : A phase I/II study. / Muroi, Kazuo; Miyamura, Koichi; Ohashi, Kazuteru; Murata, Makoto; Eto, Tetsuya; Kobayashi, Naoki; Taniguchi, Shuichi; Imamura, Masahiro; Ando, Kiyoshi; Kato, Shunichi; Mori, Takehiko; Teshima, Takanori; Mori, Masaki; Ozawa, Keiya.

In: International Journal of Hematology, Vol. 98, No. 2, 08.2013, p. 206-213.

Research output: Contribution to journalArticle

Muroi, K, Miyamura, K, Ohashi, K, Murata, M, Eto, T, Kobayashi, N, Taniguchi, S, Imamura, M, Ando, K, Kato, S, Mori, T, Teshima, T, Mori, M & Ozawa, K 2013, 'Unrelated allogeneic bone marrow-derived mesenchymal stem cells for steroid-refractory acute graft-versus-host disease: A phase I/II study', International Journal of Hematology, vol. 98, no. 2, pp. 206-213. https://doi.org/10.1007/s12185-013-1399-4
Muroi, Kazuo ; Miyamura, Koichi ; Ohashi, Kazuteru ; Murata, Makoto ; Eto, Tetsuya ; Kobayashi, Naoki ; Taniguchi, Shuichi ; Imamura, Masahiro ; Ando, Kiyoshi ; Kato, Shunichi ; Mori, Takehiko ; Teshima, Takanori ; Mori, Masaki ; Ozawa, Keiya. / Unrelated allogeneic bone marrow-derived mesenchymal stem cells for steroid-refractory acute graft-versus-host disease : A phase I/II study. In: International Journal of Hematology. 2013 ; Vol. 98, No. 2. pp. 206-213.
@article{69bf78027c7d48489669173ceee8f144,
title = "Unrelated allogeneic bone marrow-derived mesenchymal stem cells for steroid-refractory acute graft-versus-host disease: A phase I/II study",
abstract = "We conducted a multicenter phase I/II study using mesenchymal stem cells (MSCs) manufactured from the bone marrow of healthy unrelated volunteers to treat steroid-refractory acute graft-versus-host disease (aGVHD). Fourteen patients with hematological malignancies who suffered from grade II (9 patients) or III aGVHD (5) were treated. Affected organs were gut (10 patients), skin (9 patients), and liver (3 patients). Seven patients had two involved organs. The median age was 52. No other second-line agents were given. MSCs were given at a dose of 2 × 106 cells/kg for each infusion twice a week for 4 weeks. If needed, patients were continuously given MSCs weekly for an additional 4 weeks. By week 4, 13 of 14 patients (92.9 {\%}) had responded to MSC therapy with a complete response (CR; n = 8) or partial response (PR; n = 5). At 24 weeks, 11 patients (10 with CR and 1 with PR) were alive. At 96 weeks, 8 patients were alive in CR. A total of 6 patients died, attributable to the following: underlying disease relapse (2 patients), breast cancer relapse (1), veno-occlusive disease (1), ischemic cholangiopathy (1), and pneumonia (1). No clear adverse effects associated with MSC infusion were observed. Third party-derived bone marrow MSCs may be safe and effective for patients with steroid-refractory aGVHD.",
keywords = "GVHD, Mesenchymal stem cells, Steroid",
author = "Kazuo Muroi and Koichi Miyamura and Kazuteru Ohashi and Makoto Murata and Tetsuya Eto and Naoki Kobayashi and Shuichi Taniguchi and Masahiro Imamura and Kiyoshi Ando and Shunichi Kato and Takehiko Mori and Takanori Teshima and Masaki Mori and Keiya Ozawa",
year = "2013",
month = "8",
doi = "10.1007/s12185-013-1399-4",
language = "English",
volume = "98",
pages = "206--213",
journal = "International Journal of Hematology",
issn = "0925-5710",
publisher = "Springer Japan",
number = "2",

}

TY - JOUR

T1 - Unrelated allogeneic bone marrow-derived mesenchymal stem cells for steroid-refractory acute graft-versus-host disease

T2 - A phase I/II study

AU - Muroi, Kazuo

AU - Miyamura, Koichi

AU - Ohashi, Kazuteru

AU - Murata, Makoto

AU - Eto, Tetsuya

AU - Kobayashi, Naoki

AU - Taniguchi, Shuichi

AU - Imamura, Masahiro

AU - Ando, Kiyoshi

AU - Kato, Shunichi

AU - Mori, Takehiko

AU - Teshima, Takanori

AU - Mori, Masaki

AU - Ozawa, Keiya

PY - 2013/8

Y1 - 2013/8

N2 - We conducted a multicenter phase I/II study using mesenchymal stem cells (MSCs) manufactured from the bone marrow of healthy unrelated volunteers to treat steroid-refractory acute graft-versus-host disease (aGVHD). Fourteen patients with hematological malignancies who suffered from grade II (9 patients) or III aGVHD (5) were treated. Affected organs were gut (10 patients), skin (9 patients), and liver (3 patients). Seven patients had two involved organs. The median age was 52. No other second-line agents were given. MSCs were given at a dose of 2 × 106 cells/kg for each infusion twice a week for 4 weeks. If needed, patients were continuously given MSCs weekly for an additional 4 weeks. By week 4, 13 of 14 patients (92.9 %) had responded to MSC therapy with a complete response (CR; n = 8) or partial response (PR; n = 5). At 24 weeks, 11 patients (10 with CR and 1 with PR) were alive. At 96 weeks, 8 patients were alive in CR. A total of 6 patients died, attributable to the following: underlying disease relapse (2 patients), breast cancer relapse (1), veno-occlusive disease (1), ischemic cholangiopathy (1), and pneumonia (1). No clear adverse effects associated with MSC infusion were observed. Third party-derived bone marrow MSCs may be safe and effective for patients with steroid-refractory aGVHD.

AB - We conducted a multicenter phase I/II study using mesenchymal stem cells (MSCs) manufactured from the bone marrow of healthy unrelated volunteers to treat steroid-refractory acute graft-versus-host disease (aGVHD). Fourteen patients with hematological malignancies who suffered from grade II (9 patients) or III aGVHD (5) were treated. Affected organs were gut (10 patients), skin (9 patients), and liver (3 patients). Seven patients had two involved organs. The median age was 52. No other second-line agents were given. MSCs were given at a dose of 2 × 106 cells/kg for each infusion twice a week for 4 weeks. If needed, patients were continuously given MSCs weekly for an additional 4 weeks. By week 4, 13 of 14 patients (92.9 %) had responded to MSC therapy with a complete response (CR; n = 8) or partial response (PR; n = 5). At 24 weeks, 11 patients (10 with CR and 1 with PR) were alive. At 96 weeks, 8 patients were alive in CR. A total of 6 patients died, attributable to the following: underlying disease relapse (2 patients), breast cancer relapse (1), veno-occlusive disease (1), ischemic cholangiopathy (1), and pneumonia (1). No clear adverse effects associated with MSC infusion were observed. Third party-derived bone marrow MSCs may be safe and effective for patients with steroid-refractory aGVHD.

KW - GVHD

KW - Mesenchymal stem cells

KW - Steroid

UR - http://www.scopus.com/inward/record.url?scp=84882246890&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84882246890&partnerID=8YFLogxK

U2 - 10.1007/s12185-013-1399-4

DO - 10.1007/s12185-013-1399-4

M3 - Article

VL - 98

SP - 206

EP - 213

JO - International Journal of Hematology

JF - International Journal of Hematology

SN - 0925-5710

IS - 2

ER -